Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeFrom clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaTargeted treatments for multiple myeloma: specific role of carfilzomibEuropean perspective on multiple myeloma treatment strategies in 2014A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaClinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyPomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPhase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusPhase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.Novel agents for the treatment of childhood acute leukemia.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary reSpecificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human CellsThe Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaA phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaCarfilzomib boosted combination therapy for relapsed multiple myelomaCurrent strategies for treatment of relapsed/refractory multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.Salvage therapy of multiple myeloma: the new generation drugs.Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.Carfilzomib in multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.Allogeneic stem cell transplantation for multiple myeloma: is there a future?A practical review on carfilzomib in multiple myeloma.Treatment of Relapsed/Refractory Multiple Myeloma.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
P2860
Q26740359-20009776-AEFD-420F-A1B9-8F00D460665BQ26741620-241073FB-3ABC-460D-8C00-9A4250F8911BQ26782868-3B923A62-7BDF-477F-88DE-B9912D2B929BQ26862828-522944A5-4654-4283-AED5-629DB62A00EDQ26996524-63A367F4-FD7F-4A28-A528-A763107FF995Q27005966-98D5101B-6CB5-4E5E-813A-3456371E95E4Q28067148-0F6AC54C-31B6-48FA-89F3-130771540485Q28080999-04309CF2-72C6-4C80-A074-3FBAC6E7C8CBQ28082910-F09A2421-BBD4-41B6-8440-6C0D83B03721Q30802505-6C56052A-0F39-469D-BD9C-F906C329EDA8Q33412684-E3FF50EA-6902-4ADC-9E7C-CA073C9E0129Q33423168-E21A100D-1223-43BA-AEBD-490902654D4AQ33430690-F9630D8B-64BC-40D1-99F5-0C575F1F2EC6Q34464260-21C7C6BE-D40C-4F40-B9F3-C9C59BD52FB0Q34990174-603ECF66-8B19-48E3-8BC7-4C6F9064E440Q35192790-00B86977-60A3-4A52-B774-DEC7F32793D6Q35408665-39685BD2-55B1-4ACF-960C-DCD699C5516BQ35895152-1BF28868-0115-4C51-AAD1-8E0A933E5550Q36020680-AFE26CF4-8B55-4CA1-85C0-9D80BE07C90CQ36098363-A4E28467-FDBD-4F49-AEB3-D96C6B264BD2Q36444233-E61EE6A6-5F52-4C01-A698-1403A05415F1Q36671445-7D935684-FEF7-442B-9427-2AF0FC5EB073Q37652953-CAA49877-2DEE-409E-A6EF-B5FC252C3DC9Q38182683-664CAB72-1294-4F8E-8E04-A17BFC211A5FQ38187476-C4C8609C-6377-4AE7-8A62-D42908FE5204Q38218209-1D734B86-2D9E-45B0-9E84-6BD86674FB5CQ38223433-6E0EA692-08FF-4EDC-9665-B71442719D1AQ38231991-5B9D415F-DB1C-49E8-A1EA-123EB76B3CC9Q38244558-111D5F3E-35D2-4EB2-8EFA-1884B10B9476Q38271032-2A03F64F-7F2A-42CF-9A86-540826FB78CAQ38400460-6EF91998-01CA-405F-9F19-1E9D2A98CE79Q38545607-9114A47C-E234-407F-9648-0E59DBF014BFQ38630472-67B9CBA8-4C56-4B7F-84C8-162DEE239857Q38670280-47065341-5E29-41DE-8F7C-7D0F3F82C5DEQ38685796-AE05622A-86A8-4DB6-8BBA-A3F5A59C3E7CQ38740271-09E0AEDA-5ADC-44CE-88CB-876393A15B9AQ38970597-EE79377D-B47C-45D3-9532-79B107BC3813Q38989789-1CFFEADF-5DC4-4A2B-A613-3A882CFC800BQ39138108-5BC65E5E-1D70-4196-81EC-662828568F53Q39177792-5BF2FA21-39E1-492F-A899-398003C5FBCC
P2860
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase 2 dose-expansion study ( ...... progressive multiple myeloma.
@ast
Phase 2 dose-expansion study ( ...... progressive multiple myeloma.
@en
type
label
Phase 2 dose-expansion study ( ...... progressive multiple myeloma.
@ast
Phase 2 dose-expansion study ( ...... progressive multiple myeloma.
@en
prefLabel
Phase 2 dose-expansion study ( ...... progressive multiple myeloma.
@ast
Phase 2 dose-expansion study ( ...... progressive multiple myeloma.
@en
P2093
P2860
P1433
P1476
Phase 2 dose-expansion study ( ...... progressive multiple myeloma.
@en
P2093
David S Siegel
Edward Kavalerchik
Melissa Alsina
Michael Wang
Tom Martin
William Bensinger
P2860
P304
P356
10.1182/BLOOD-2013-07-511170
P407
P577
2013-09-06T00:00:00Z